Dual Immunotherapy a Winner for Melanoma Brain Mets Dual Immunotherapy a Winner for Melanoma Brain Mets

A combination of two checkpoint inhibitors (nivolumab and ipilimumab) achieved ' clinically meaningful ' efficacy in patients with asymptomatic, untreated melanoma metastases to the brain.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news